Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageDaVita is a leading healthcare provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, we have been a leader in clinical quality and innovation for more than 25 years. We care for patients at every stage and setting along their kidney health journey–from slowing the progression of kidney disease to helping support transplantation. This includes ensuring they are supported at home, in our dialysis centers, in the hospital and in skilled nursing facilities.
In the company’s own words · 10-K filed Feb 11, 2026 · SEC EDGAR
Business segments
Q2 2026 · $5.35BThe company’s own SEC segment disclosure.
- U.S.Dialysis With Intersegment$2.99B56%
- U.S.Dialysis And Related Lab Services$1.75B33%
- Other Operating Segments With Intersegment$372.4M7%
- All Other$236.4M4%
DaVita (DVA) reported revenue of $3.55B in Q2 2026 (quarter ended Jun 30, 2026), up 5.2% from the same quarter a year earlier. That came with net income of $265M (7.5% of revenue). For the full year FY2025, revenue was $13.6B (+6.5% year on year) and net income $747M. Its largest segment in Q2 2026 was U.S.Dialysis With Intersegment at $2.99B, 56% of the disclosed total, well ahead of U.S.Dialysis And Related Lab Services at 33%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Medical Care Facilities
The closest names by size in the same industry